Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.In the final episode of this 3-part Oncology Unplugged series, Ch...
with lorlatinib treatment Fanfan Chu1 · Wenxi Zhang1 · Hong Hu2 Received: 19 March 2024 / Accepted: 11 September 2024 © The Author(s) 2024 OPEN Abstract To explore the presentation and control of CNS adverse reactions in patients with ALK-positive NSCLC treated with...
ALK-Positive NSCLC: Crizotinib Extends Survival, Called New Standard of CareCarlson, Robert H.Free Access CHICAGO—ALK (anaplastic lymphoma kinase) represents one of the newest tyrosine kinase targets in lung cancer. A Phase I trial reported last fall (Kwak et al: NEJM 2010;363-1693-...
Thus, ceritinib is a valuable treatment option for patients with ALK-positive advanced NSCLC who have already received crizotinib therapy.doi:10.1007/s11523-016-0460-7DeeksEmma D.Springer International PublishingTargeted OncologyDeeks ED: Ceritinib: a review in ALK-positive advanced NSCLC. Target Oncol...
July 12, 2011 —Crizotinib, a new targeted drug aimed at certain patients with nonsmall-cell lung cancer (NSCLC), is expected to be approved before the end of the year. The drug targets anALKrearrangement, which is found in about 4% to 5% of patients with NSCLC; in these patients it ...
Catalog of 5′ fusion partners in ALK-positive NSCLC circa 2020. JTO Clin. Res. Rep. 1, 100015 (2020). PubMed PubMed Central Google Scholar Hrustanovic, G. et al. RAS–MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21, 1038–...
ALK NSCLC alectinib lorlatinib acquired resistance crizotinib ceritinib Sorry, something went wrong. Please try again and make sure cookies are enabledReferences 1. P.L. Chia, T. John, A. Dobrovic, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clin...
June 3, 2013 — The targeted agentcrizotinib(Xalkori) is superior to standard chemotherapy in patients with previously treated advanced nonsmall-cell lung cancer (NSCLC) and anaplasticlymphomakinase (ALK) gene rearrangement, according to a phase 3 open-label trialpublished onlineJune 1 in theNew En...
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17:52. Article PubMed PubMed Central Google Scholar Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, et al. Antibody targeting of anaplastic...
Because crizotinib has been launched last year and ALK-positive NSCLC is rare, the clinical experience of crizotinib in practice is limited. Our aim is to assess an efficacy and adverse event (AE) of crizotinib for patients with advanced NSCLC in our department. Methods: We retrospectively ...